CN107001326A - 抗非小细胞肺癌的喹啉衍生物 - Google Patents

抗非小细胞肺癌的喹啉衍生物 Download PDF

Info

Publication number
CN107001326A
CN107001326A CN201580066275.8A CN201580066275A CN107001326A CN 107001326 A CN107001326 A CN 107001326A CN 201580066275 A CN201580066275 A CN 201580066275A CN 107001326 A CN107001326 A CN 107001326A
Authority
CN
China
Prior art keywords
compound
small cell
cell lung
milligrams
lung cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201580066275.8A
Other languages
English (en)
Other versions
CN107001326B (zh
Inventor
王训强
缪亚东
周敏
王善春
杨玲
施伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN107001326A publication Critical patent/CN107001326A/zh
Application granted granted Critical
Publication of CN107001326B publication Critical patent/CN107001326B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)

Abstract

本申请提供了一种抗非小细胞肺癌的喹啉衍生物。本申请所提供的1‑[[[4‑(4‑氟‑2‑甲基‑1H‑吲哚‑5‑基)氧基‑6‑甲氧基喹啉‑7‑基]氧基]甲基]环丙胺或其药学上可接受的盐可用于治疗非小细胞肺癌，且相对于安慰剂，能显著提高非小细胞肺癌患者的无进展生存期。本申请所提供的1‑[[[4‑(4‑氟‑2‑甲基‑1H‑吲哚‑5‑基)氧基‑6‑甲氧基喹啉‑7‑基]氧基]甲基]环丙胺或其药学上可接受的盐可用于治疗肺腺癌，且相对于安慰剂，能显著提高肺腺癌患者的无进展生存期。

Description

PCT国内申请，说明书已公开。

Claims (34)

  1. PCT国内申请，权利要求书已公开。
CN201580066275.8A 2014-12-09 2015-12-09 抗非小细胞肺癌的喹啉衍生物 Active CN107001326B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014107493940 2014-12-09
CN201410749394 2014-12-09
PCT/CN2015/096777 WO2016091168A1 (zh) 2014-12-09 2015-12-09 抗非小细胞肺癌的喹啉衍生物

Publications (2)

Publication Number Publication Date
CN107001326A true CN107001326A (zh) 2017-08-01
CN107001326B CN107001326B (zh) 2020-05-05

Family

ID=56106719

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580066275.8A Active CN107001326B (zh) 2014-12-09 2015-12-09 抗非小细胞肺癌的喹啉衍生物

Country Status (7)

Country Link
US (2) US10307412B2 (zh)
EP (1) EP3231797B1 (zh)
JP (1) JP6865684B2 (zh)
CN (1) CN107001326B (zh)
AU (1) AU2015360095B2 (zh)
ES (1) ES2793286T3 (zh)
WO (1) WO2016091168A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019223672A1 (zh) * 2018-05-22 2019-11-28 正大天晴药业集团股份有限公司 用于治疗非小细胞肺癌的喹啉衍生物
CN112274511A (zh) * 2019-07-22 2021-01-29 正大天晴药业集团股份有限公司 用于治疗移植物抗宿主病的喹啉衍生物
CN114727984A (zh) * 2019-09-25 2022-07-08 德彪药业国际股份公司 治疗患有局部晚期鳞状细胞癌的患者的给药方案
CN114761010A (zh) * 2019-11-25 2022-07-15 正大天晴药业集团股份有限公司 喹唑啉衍生物或其盐的联用药物组合物及其用途

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105311029A (zh) 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物
CN105311030B (zh) * 2014-06-06 2020-03-24 正大天晴药业集团股份有限公司 用于抗肿瘤的螺取代化合物
JP6865684B2 (ja) 2014-12-09 2021-04-28 チア タイ チオギン ファーマスーチカル グループ コーポレイテッド，リミテッド 非小細胞肺癌に対するキノリン誘導体
US9751859B2 (en) 2015-05-04 2017-09-05 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts
CN114790207B (zh) 2015-07-11 2023-07-25 南京爱德程医药科技有限公司 作为pi3k/mtor抑制剂的被取代的吡啶基取代的稠合喹啉化合物
CN107296811B (zh) 2016-04-15 2022-12-30 正大天晴药业集团股份有限公司 一种用于治疗胃癌的喹啉衍生物
WO2019166012A1 (zh) 2018-03-02 2019-09-06 正大天晴药业集团股份有限公司 作为c-Met激酶抑制剂的化合物的结晶及其制备方法和用途
US20220160700A1 (en) * 2018-07-18 2022-05-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Therapeutic combination of quinoline derivative and antibody
CN117085016A (zh) * 2018-09-18 2023-11-21 正大天晴药业集团股份有限公司 用于治疗小细胞肺癌的喹啉衍生物
WO2020057536A1 (zh) * 2018-09-18 2020-03-26 正大天晴药业集团股份有限公司 用于治疗脑肿瘤的喹啉衍生物
CN113518621A (zh) * 2019-03-07 2021-10-19 南京爱德程医药科技有限公司 按顺序使用卡奎替尼(安罗替尼)和标准化学疗法或免疫疗法的组合以治疗癌症

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101809012A (zh) * 2007-03-14 2010-08-18 南京爱德程医药科技有限公司 作为血管生成抑制剂的螺取代化合物
CN102344438A (zh) * 2010-08-01 2012-02-08 江苏正大天晴药业股份有限公司 喹啉衍生物的结晶及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
AU2008218806B2 (en) 2007-02-20 2011-12-01 Novartis Ag Imidazoquinolines as dual lipid kinase and mTOR inhibitors
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
WO2009155527A2 (en) 2008-06-19 2009-12-23 Progenics Pharmaceuticals, Inc. Phosphatidylinositol 3 kinase inhibitors
IT1393351B1 (it) 2009-03-16 2012-04-20 Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi
US9550781B2 (en) * 2011-11-14 2017-01-24 Centaurus Biopharma Co., Ltd. Kinase modulating compounds, compositions containing the same and use thereof
WO2014113616A1 (en) 2013-01-18 2014-07-24 Advenchen Pharmaceuticals, LLC Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and its crystalline
CN104513229A (zh) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
CN105311030B (zh) * 2014-06-06 2020-03-24 正大天晴药业集团股份有限公司 用于抗肿瘤的螺取代化合物
CN105311029A (zh) 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物
EP3169687B1 (en) 2014-07-14 2019-01-02 Advenchen Pharmaceuticals, Nanjing Ltd. FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS
JP6865684B2 (ja) 2014-12-09 2021-04-28 チア タイ チオギン ファーマスーチカル グループ コーポレイテッド，リミテッド 非小細胞肺癌に対するキノリン誘導体
US9751859B2 (en) 2015-05-04 2017-09-05 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts
CN114790207B (zh) 2015-07-11 2023-07-25 南京爱德程医药科技有限公司 作为pi3k/mtor抑制剂的被取代的吡啶基取代的稠合喹啉化合物
CN107296811B (zh) 2016-04-15 2022-12-30 正大天晴药业集团股份有限公司 一种用于治疗胃癌的喹啉衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101809012A (zh) * 2007-03-14 2010-08-18 南京爱德程医药科技有限公司 作为血管生成抑制剂的螺取代化合物
CN102344438A (zh) * 2010-08-01 2012-02-08 江苏正大天晴药业股份有限公司 喹啉衍生物的结晶及其制备方法

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019223672A1 (zh) * 2018-05-22 2019-11-28 正大天晴药业集团股份有限公司 用于治疗非小细胞肺癌的喹啉衍生物
CN112105361A (zh) * 2018-05-22 2020-12-18 正大天晴药业集团股份有限公司 用于治疗非小细胞肺癌的喹啉衍生物
CN112274511A (zh) * 2019-07-22 2021-01-29 正大天晴药业集团股份有限公司 用于治疗移植物抗宿主病的喹啉衍生物
CN112274511B (zh) * 2019-07-22 2024-04-02 正大天晴药业集团股份有限公司 用于治疗移植物抗宿主病的喹啉衍生物
CN114727984A (zh) * 2019-09-25 2022-07-08 德彪药业国际股份公司 治疗患有局部晚期鳞状细胞癌的患者的给药方案
CN114761010A (zh) * 2019-11-25 2022-07-15 正大天晴药业集团股份有限公司 喹唑啉衍生物或其盐的联用药物组合物及其用途
CN114761010B (zh) * 2019-11-25 2024-04-16 正大天晴药业集团股份有限公司 喹唑啉衍生物或其盐的联用药物组合物及其用途

Also Published As

Publication number Publication date
AU2015360095B2 (en) 2020-02-27
US10307412B2 (en) 2019-06-04
CN107001326B (zh) 2020-05-05
US10888559B2 (en) 2021-01-12
EP3231797A4 (en) 2018-05-09
JP6865684B2 (ja) 2021-04-28
ES2793286T3 (es) 2020-11-13
JP2017537126A (ja) 2017-12-14
WO2016091168A1 (zh) 2016-06-16
EP3231797A1 (en) 2017-10-18
US20190298712A1 (en) 2019-10-03
US20170304290A1 (en) 2017-10-26
EP3231797B1 (en) 2020-02-26
AU2015360095A1 (en) 2017-07-27

Similar Documents

Publication Publication Date Title
CN107001326A (zh) 抗非小细胞肺癌的喹啉衍生物
CN106999484A (zh) 治疗非小细胞肺癌的喹啉衍生物
CN106456626A (zh) 喹啉衍生物用于治疗软组织肉瘤的方法和用途以及用于治疗软组织肉瘤的药物组合物
CN106413712A (zh) 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物
CN109069500A (zh) 一种用于治疗胃癌的喹啉衍生物
CN108601778A (zh) 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒
KR20210070234A (ko) 암 치료 방법
CN112584834B (zh) 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物
WO2020057536A1 (zh) 用于治疗脑肿瘤的喹啉衍生物
CN106999485A (zh) 抗肺鳞癌的喹啉衍生物
CN115487188B (zh) 治疗鼻咽癌的喹啉衍生物
AU2020386903A1 (en) Dosing regimens for a protein kinase C inhibitor
CN112105361A (zh) 用于治疗非小细胞肺癌的喹啉衍生物
CN111110681A (zh) 喹啉衍生物联合卡培他滨在治疗肝癌的用途
WO2020057539A1 (zh) 用于治疗小细胞肺癌的喹啉衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1238631

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant